Exploring the Tumor-Associated Risk of Mesenchymal Stem Cell Therapy in Veterinary Medicine.
Soyoung JeungSung-Soo KimJaegon AhSanghyuk SeoUmair JanHyejin LeeJeong Ik LeePublished in: Animals : an open access journal from MDPI (2024)
Mesenchymal stem cell (MSC) therapy has been actively applied in veterinary regenerative medicine to treat various canine and feline diseases. With increasing emphasis on safe cell-based therapies, evaluations of their tumorigenic potential are in great demand. However, a direct confirmation of whether tumors originate from stem cells or host cells is not easily achievable. Additionally, previous studies evaluating injections of high doses of MSCs into nude mice did not demonstrate tumor formation. Recent research focused on optimizing MSC-based therapies for veterinary patients, such as MSC-derived extracellular vesicles in treating different diseases. This progress also signifies a broader shift towards personalized veterinary medicine, where treatments can be tailored to individual pets based on their unique genetic profiles. These findings related to different treatments using MSCs emphasize their future potential for veterinary clinical applications. In summary, because of lower tumor-associated risk of MSCs as compared to embryonic and induced pluripotent stem cells, MSCs are considered a suitable source for treating various canine and feline diseases.
Keyphrases
- mesenchymal stem cells
- umbilical cord
- cell therapy
- stem cells
- bone marrow
- induced pluripotent stem cells
- end stage renal disease
- newly diagnosed
- induced apoptosis
- chronic kidney disease
- ejection fraction
- gene expression
- single cell
- human health
- cell cycle arrest
- dna methylation
- prognostic factors
- patient reported outcomes
- copy number
- oxidative stress
- risk assessment
- smoking cessation
- skeletal muscle
- patient reported
- endoplasmic reticulum stress
- drug induced